A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Latest Information Update: 07 Feb 2024
Price :
$35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Expanded access
- 31 Jan 2024 Status changed from recruiting to completed.
- 30 Jun 2017 New trial record